Physician profile
Alexandra Below
NPI 1871152249
$2,283.06
in general payments reported to CMS, 2019-2025
26 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.30 · 2022: $287 · 2023: $111 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,940 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.97 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $328.41 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Sk Life Science, INC. | $221.21 | 2025 | Xcopri |
| Lilly USA, LLC | $212.02 | 2025 | Amyvid, Kisunla |
| Lundbeck LLC | $207.56 | 2025 | Vyepti, Rexulti |
| Neurelis, INC. | $144.30 | 2025 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $128.48 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $110.35 | 2025 | Austedo Xr |
| Ucb, INC. | $109.19 | 2021-2025 | Briviact, Nayzilam |
| Tris Pharma INC | $107.52 | 2025 | Onyda Xr |
| Neuropace, INC. | $101.18 | 2022 | |
| Neurocrine Biosciences, INC. | $87.76 | 2025 | |
| Collegium Pharmaceutical, INC. | $86.79 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $84.90 | 2025 | Hyqvia |
| Eisai INC. | $67.79 | 2025 | |
| Tg Therapeutics, INC. | $48.94 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35.15 | 2022 | |
| Argenx US, INC. | $25.45 | 2025 | Vyvgart Hytrulo |
| Corium, LLC | $24.88 | 2025 | Azstarys |
| Pfizer INC. | $24.57 | 2025 | |
| Phathom Pharmaceuticals, INC. | $22.09 | 2025 | Voquezna |
| Impel Pharmaceuticals LLC | $19.58 | 2025 | Trudhesa |
| Amneal Pharmaceuticals LLC | $19.40 | 2025 | Brekiya |
| Alexion Pharmaceuticals, INC. | $18.65 | 2025 | |
| Neos Therapeutics, LP | $16.47 | 2025 | Adzenys Xr-Odt |
| Vertical Pharmaceuticals, LLC | $15.85 | 2025 | Relexxii |
| Celgene Corporation | $14.57 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Below listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.